NCT06483555 2025-04-16
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT02273362 2024-03-26
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00617708 2022-02-08
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT00769483 2020-09-03
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00307736 2017-05-10
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT00260364 2016-10-14
TARGET
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00049101 2013-06-24
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00293436 2012-09-17
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
University of California, San Francisco
Phase 1/2 Withdrawn
NCT00791544 2010-08-04
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
Sanofi
Phase 1/2 Terminated